Genprex, Inc. Files 8-K Report
Ticker: GNPX · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1595248
Sentiment: neutral
Topics: 8-K, filing, SEC
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K. Check for updates on financials & events.
AI Summary
On November 21, 2025, Genprex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific new events, financial figures, or material agreements were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Genprex, Inc. has made official disclosures to the SEC, which could contain important updates for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without specific negative or positive material events detailed in the provided text, making the immediate risk level low.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- November 21, 2025 (date) — Date of report
- 1601 Trinity Street, Bldg. B, Suite 3.322, Austin, TX 78712 (address) — Business and Mail Address
- 512-537-7997 (phone_number) — Business Phone
- 3300 Bee Cave Road, #650-227, Austin, TX 78746 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Genprex, Inc.?
The 8-K filing is for "Other Events" and "Financial Statements and Exhibits," indicating disclosures related to the company's financial status and significant occurrences.
On what date was this 8-K report filed?
The 8-K report was filed on November 21, 2025.
What is Genprex, Inc.'s state of incorporation?
Genprex, Inc. is incorporated in Delaware.
What is the business address of Genprex, Inc.?
The business address is 1601 Trinity Street, Bldg. B, Suite 3.322, Austin, TX 78712.
What is the SIC code for Genprex, Inc.?
The Standard Industrial Classification (SIC) code for Genprex, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 677 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2025-11-21 16:46:00
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $75,000,000 — ng an aggregate offering price of up to $75,000,000 (the "Shares"), pursuant to that certai
- $14,796,375 — n stock for aggregate gross proceeds of $14,796,375 under the Sales Agreement pursuant to t
Filing Documents
- gnpx20251120_8k.htm (8-K) — 29KB
- ex_891383.htm (EX-5.1) — 9KB
- lowensandlogo.jpg (GRAPHIC) — 16KB
- 0001437749-25-036016.txt ( ) — 193KB
- gnpx-20251121.xsd (EX-101.SCH) — 3KB
- gnpx-20251121_def.xml (EX-101.DEF) — 12KB
- gnpx-20251121_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251121_pre.xml (EX-101.PRE) — 12KB
- gnpx20251120_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 21, 2025, Genprex, Inc. (the "Company") filed a prospectus supplement dated November 21, 2025 (the "Prospectus Supplement") with the Securities and Exchange Commission for the offer and sale of additional shares of its common stock, par value $0.001 per share having an aggregate offering price of up to $75,000,000 (the "Shares"), pursuant to that certain At the Market Offering Agreement, dated December 13, 2023, by and between the Company and H.C. Wainwright & Co., LLC, acting as agent (the "Sales Agreement"). The Prospectus Supplement amends and supplements the information contained in the prospectus, dated June 9, 2023 (the "Base Prospectus"), filed as part of the Company's registration statement on Form S-3 (File No. 333-271386), as previously amended and supplemented by the Company's prospectus supplements dated November 10, 2025, December 20, 2024, November 8, 2024, August 16, 2024, May 20, 2024 and December 13, 2023 (the "Prior Prospectuses," and collectively with the Base Prospectus, the "ATM Prospectus"). The Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information therein amends or supersedes the information contained in the ATM Prospectus. The Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus and any future amendments or supplements thereto. The Company has previously sold 796,065 shares of its common stock for aggregate gross proceeds of $14,796,375 under the Sales Agreement pursuant to the Prior Prospectuses. A copy of the opinion of Lowenstein Sandler LLP relating to the legality of the Shares covered by the Prospectus Supplement is filed as Exhibit 5.1 attached hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 5.1 Opinion of Lowenstein Sandler LLP . 23.1 Consent of Lowenstein Sandler LLP (included in Exhibit 5.1) . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 21, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)